Abivax Obefazimod Phase 3 Success Lifts European Biotech Stocks
Abivax shares surge 38% after obefazimod meets Phase 3 endpoints in ulcerative colitis maintenance therapy, driving European biotech rally and investor confidence in novel IBD treatments.